GRNA · Greenlight Biosciences Holdings, Pbc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.82M | - | $362.0K | $493.0K | $325.0K | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $23.17M | - | $29.94M | $44.15M | $8.01M | - | - | - | - | - |
| SG&A | $8.94M | - | $8.03M | $9.58M | $29.02M | - | $2.56M | $337.6K | - | - |
| Total Operating Expenses | $32.11M | - | $27.77M | $53.73M | $37.04M | - | - | - | $1.19M | - |
| D&A | $2.33M | - | - | - | $1.11M | - | - | - | - | - |
| Operating Income | ($28.29M) | - | ($36.24M) | ($51.96M) | ($36.78M) | - | ($2.56M) | ($337.6K) | ($1.19M) | - |
| Interest Expense | $1.01M | - | - | - | $311.0K | - | - | - | - | - |
| Income Tax | - | - | $1.09M | - | - | - | - | - | - | - |
| Net Income | ($28.47M) | - | ($38.16M) | ($51.93M) | ($38.21M) | - | ($1.53M) | ($3.02M) | $1.04M | - |
| EPS - Basic | ($0.34) | - | ($0.30) | ($0.42) | - | - | - | - | - | - |
| EPS - Diluted | ($0.34) | - | ($0.27) | ($0.28) | - | - | - | - | $0.21 | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.35M | $68.10M | $98.35M | $44.13M | $83.22M | $67.5K | $158.3K | $97.4K | $197.5K | $156.8K |
| Accounts Receivable | - | - | $0 | $10.00M | $5.00M | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.07M | $839.0K | $3.03M | $4.16M | $7.55M | - | - | - | - | - |
| Current Assets | $37.70M | $71.31M | $109.31M | $64.00M | $96.95M | $530.0K | $856.6K | $932.9K | $156.8K | - |
| Total Assets | $113.69M | $148.60M | $151.42M | $98.81M | $122.43M | $207.54M | $207.87M | $207.94M | $208.12M | $337.9K |
| Current Liabilities | $31.19M | $35.56M | $32.42M | $55.22M | $29.52M | $12.32M | $3.64M | $1.16M | $1.01M | $315.4K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $91.75M | $100.54M | $67.00M | $85.08M | $58.60M | $28.21M | $16.98M | $15.52M | $302.5K | - |
| Stockholders' Equity | $21.94M | $48.06M | $84.42M | $13.72M | $63.83M | ($27.66M) | $24.1K | $5.00M | $5.00M | $22.5K |
| Retained Earnings | ($449.11M) | ($420.64M) | ($381.87M) | ($343.72M) | ($291.79M) | ($27.66M) | ($16.11M) | ($1.98M) | $1.04M | ($2.5K) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($31.06M) | - | - | - | ($49.47M) | - | - | - | ($1.18M) | - |
| Investing Cash Flow | ($1.61M) | - | - | - | ($250.0K) | - | - | - | ($207.00M) | - |
| Financing Cash Flow | ($2.99M) | - | - | - | $102.45M | - | $25.0K | - | $208.22M | - |
| CapEx | $1.61M | - | - | - | $4.69M | - | - | - | - | - |
| Free Cash Flow | ($32.67M) | - | - | - | ($54.16M) | - | - | - | - | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -740.6% | - | -10010.2% | -10539.6% | -11316.6% | - | - | - | - | - |
| EBITDA margin | -679.5% | - | - | - | -10974.2% | - | - | - | - | - |
| Net margin | -745.3% | - | -10540.9% | -10532.7% | -11756.0% | - | - | - | - | - |
| Free cash flow margin | -855.2% | - | - | - | -16663.4% | - | - | - | - | - |
| FCF / Net income | 1.15 | - | - | - | 1.42 | - | - | - | - | - |
| R&D / Revenue | 606.5% | - | 8271.8% | 8955.6% | 2465.2% | - | - | - | - | - |
| SG&A / Revenue | 234.1% | - | 2216.9% | 1942.6% | 8930.5% | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.0% | - | -25.2% | -52.6% | -31.2% | - | -0.7% | -1.5% | 0.5% | - |
| Return on equity | -129.8% | - | -45.2% | -378.3% | -59.9% | - | -6328.5% | -60.5% | 20.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.21 | 2.01 | 3.37 | 1.16 | 3.28 | 0.04 | 0.24 | 0.81 | 0.16 | - |
| Quick ratio | 1.21 | 2.01 | 3.37 | 1.16 | 3.28 | 0.04 | 0.24 | 0.81 | 0.16 | - |
| Cash ratio | 1.04 | 1.91 | 3.03 | 0.80 | 2.82 | 0.01 | 0.04 | 0.08 | 0.20 | 0.50 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -28.1x | - | - | - | -118.3x | - | - | - | - | - |
| Equity multiplier | 5.18 | 3.09 | 1.79 | 7.20 | 1.92 | -7.50 | 8617.25 | 41.59 | 41.62 | 15.04 |
| Liabilities / Assets | 0.81 | 0.68 | 0.44 | 0.86 | 0.48 | 0.14 | 0.08 | 0.07 | 0.00 | - |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | - | 0.00 | 0.00 | 0.00 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | 0d | 7404d | 5615d | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1075.4% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 23.1% | - | -1317.3% | -15291.8% | -2990.4% | - | - | - | - | - |
| Net income growth (YoY) | 25.5% | - | -2399.6% | -1616.9% | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 39.7% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -65.6% | - | 349850.3% | 174.5% | 1176.5% | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing GreenLight Biosciences Holdings against the 5 most active filers in the same SIC group.